Rhinomed

TRY our products Today.

Select a product below to learn more and purchase online.

RNO SIGNS 12 YEAR LICENSING AGREEMENT WITH USA’S LARGEST MEDICAL CANNABIS OPERATOR

Rhinomed (ASX:RNO) is pleased to advise investors it has signed a 12-year exclusive licensing agreement of its nasal platform technology with Columbia Care LLC.
Read More
APPENDIX 4E PRELIMINARY FINAL REPORT

Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today released the Appendix 4E Preliminary Final Report
Read More
BUSINESS UPDATE – JUNE QUARTER CASH FLOW REPORT

Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k - a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17.
Read More